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The gene responsible for neurofibromatosis type 1 
(NFl), one of the more common inherited human disorders, 
was identified recently, and segments of it were cloned. 
Two translocation breakpoints that interrupt the NFl 
gene in NFl patients flank a 60-kb segment of DNA that 
contains the EVIZA locus (previously reported as the EV12 
locus), the human homolog of a mouse gene, Evi-2A, impli- 
cated in retrovirus-induced murine myeloid tumors. 
EVI2A lies within an intron of the NFl gene and is tran- 
scribed from telomere toward centromere, opposite to the 
direction of transcription of the NFl gene. Here we de- 
scribe a second locus, EVI2B, also located between the two 
NFl translocation breakpoints. Full-length cDNAs from 
the EVZZB locus detect a 2.1-kb transcript in bone 
marrow, peripheral blood mononuclear cells, and fibro- 
blasts. Sequencing studies predict an EVI2B protein of 448 
amino acids that is proline-rich and contains an N-terminal 
signal peptide, an extracellular domain with four potential 
glycosylation sites, a single hydrophobic transmembrane 
domain, and a cytoplasmic hydrophilic domain. At the level 
of genomic DNA the EVI2B locus lies within the same in- 
tron of the NFl gene as EVI2A and contains a 57-bp B’exon 
that is noncoding, an 8-kb intron, and a 2078-bp 3’ exon 
that includes the entire open reading frame. EVI2B is tran- 
scribed in the same direction as EVI2A; its 5’exon lies only 
4 kb downstream from the 3’ exon of the EVI2A locus. In 
the mouse the 5’ exon of the homologous gene, Evi-2B, lies 
approximately 2.8 kb from the 3’ end of Evi-2A, in the 
midst of a cluster of viral integration sites identified in ret- 
rovirus-induced myeloid tumors; thus, Evi-2B may func- 
tion as an oncogene h these tUIUOrS. CC) is91 Academic Press, Inc. 
INTRODUCTION 
Neurofibromatosis type 1 (NFl), originally de- 
scribed by von Recklinghausen, is an autosomal domi- 
nant disorder occurring at a frequency of 1 in 3000 
(Crowe et al., 1956). NFl is a clinical diagnosis de- 
fined by criteria agreed upon in a consensus confer- 
ence at the National Institutes of Health (Stumpf et 
al., 1987). The most common physical signs of this 
condition are multiple subcutaneous nodules (neuro- 
fibromas) and hyperpigmented patches of skin (cafe- 
au-lait spots). Patients with NFl are at significantly 
increased risk for development of malignancies (e.g., 
see Riccardi and Eichner, 1986), including malignant 
schwannoma, pheochromocytoma, and rhabdomyo- 
sarcoma. 
Recently, the NFl gene was identified and seg- 
ments of it were cloned (Cawthon et al., 1990a; Visko- 
chil et al., 1990a; Wallace et al., 1990a). Two balanced 
translocations involving chromosome band 17q11.2 
have been found in two unrelated NFl patients 
(Schmidt et al., 1987; Ledbetter et al., 1989; Menon et 
al., 1989); the breakpoints on chromosome 17 lie ap- 
proximately 60 kb apart (O’Connell et al., 1990). An 
RNA PCR-based assay indicated that both transloca- 
tions prevent transcription of the NFl gene (Wallace 
et al., 1990a) on the affected chromosome 17, and hy- 
bridization studies showed that NFl cDNAs are in- 
terrupted by both the t( 17;22) break (Viskochil et al., 
1990a) and the more centromeric t(1;17) break (Xu et 
al., 1990). We have previously reported the mapping 
of the human homolog of a mouse gene implicated in 
leukemogenesis, hi-2A (ecotropic viral integration 
site 2A, originally designated Eui-2: Buchberg et al., 
1988, 1989, 1990), into the region between the two 
NFl translocation breakpoints (O’Connell et al., 
1990) and the characterization of the human EVI2A 
transcript (previously referred to as EV12: Cawthon 
et al., 199Ob). The orientation of EVI2A (Cawthon et 
al., 1990b) is opposite that of NFl (Cawthon et al., 
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1990a; Viskochil et al., 1990a; Wallace et al., 1990a), 
and by hybridization studies and sequence compari- 
son, NFl exons that map between the translocation 
breakpoints do not overlap with EVIZA exons. There- 
fore, EVIZA is transcribed from the anti-sense strand 
of the NFl gene and is entirely contained within an 
intron of the NFl gene. 
Here we show that a second transcript, EVIZB, also 
maps into the interval between the two NFl translo- 
cation breakpoints. We examine the pattern of 
EVIZB gene expression in several tissues, report the 
sequences of human EVIZB cDNA and genomic 
clones, predict features of the encoded protein prod- 
uct, and show the location and orientation of the gene 
on the genomic map of the breakpoint region. We 
show that in mouse genomic DNA, many ecotropic 
retroviral DNA integrations that are in the vicinity of 
the murine Evi-2A locus and are associated with my- 
eloid tumor formation are located and oriented in a 
fashion consistent with disrupting or altering the reg- 
ulation of the murine homolog of human EVIZB 
(hence the choice of EVIZB as the name for the new 
locus); these results suggest that Evi-2B may function 
as an oncogene in murine myeloid tumors. (EVI2B is 
fully characterized for the first time here; however, 
this locus was referred to briefly in previous publica- 
tions by other names: RCl in Cawthon et al., 1990a,b, 
and Viskochil et al., 1990b; NFI-c2 in Wallace et al., 
1990a,b). 
MATERIALS AND METHODS 
cDNA Libraries and Plaque Screening 
Two cDNA libraries were screened. A normal adult 
human bone marrow cDNA library in XgtlO, cata- 
logue number HL1058a, was purchased from CLON- 
TECH Laboratories, Inc. (Palo Alto, CA). Phage 
from the library were incubated with Escherichia coli 
strain LE392 and plated according to the manufac- 
turer’s instructions. A human cDNA library in Xgtll 
(Bonthron et al., 1985) constructed from the lym- 
phoid cell line GM-1715 (Human Genetic Mutant 
Cell Repository, Camden, NJ), derived from an immu- 
nodeficient patient (partial adenosine deaminase de- 
ficiency and impaired T cell immunity), was also 
screened. In addition, 5 X lo5 pfu (plaque forming 
units) from this library were incubated with E. coli 
strain Y 1088 and plated at a density of 25,000 pfu per 
150-mm plate (176.7 cm*). Duplicate plaque lifts were 
made with 02pm pore-size Biotrans filters (Pall Bio- 
dyne) or 0.45-pm pore-size Immobilon-NC nitrocellu- 
lose filters (Millipore Corp.) by the method of Benton 
and Davis (1977). Radiolabeling of DNA probes was 
done according to Feinberg and Vogelstein (1984). 
First, inserts were separated from vector by restric- 
tion enzyme digestion and gel electrophoresis in low- 
melting agarose (NuSieve GTG agarose, FMC Bio- 
Products, Rockland, ME). DNA in gel slices was used 
directly for radiolabeling. 
For the screening of the bone marrow cDNA li- 
brary, the cDNA library filters were prehybridized in 
50% formamide, 5~ SSC, 50 mM NaPO, (pH 6.5), 2~ 
Denhardt’s solution, 5% dextran sulfate, and 500 pg/ 
ml sheared, denatured human DNA at 42°C for 2 h. 
Separate prehybridization of the radiolabeled probes 
was simultaneously carried out in a solution of the 
same composition except that 50 Kg/ml of DNA from 
the vector used to clone the probe was included. After 
prehybridization the probe and filters were combined 
and hybridization was carried out for 4-16 h at 42°C. 
When genomic cosmids were used as probes, washes 
were in 2~ SSC, 0.1% SDS at room temperature. 
When cDNAs were used as probes, washes were in 
0.1X SSC, 0.1% SDS at 55-65°C. After washing, 
filters were placed on X-Omat AR film with an inten- 
sifying screen at -70°C. 
For the screening of the lymphoid cell line cDNA 
library, filters were prehybridized and hybridized in 
6X SSC, 0.5% SDS, 2~ Denhardt’s solution, 1 mM 
EDTA, and 100 pug/ml sheared, denatured salmon 
sperm DNA at 65°C. Before hybridization was carried 
out, the radiolabeled probes were preannealed with 
250 pg/ml sheared human placental DNA for 2 h. Hy- 
bridization was carried out for 12-24 h at 65”C, after 
which the filters were washed at 65°C to a final strin- 
gency of 0.1X SSC, 0.1% SDS. The signal was visual- 
ized on X-Omat AR film (Kodak) with an intensify- 
ing screen at -70°C overnight. 
Cell Lines and Tissues 
Lymphoblastoid cell lines from normal and NFl 
individuals, established by transformation of periph- 
eral blood mononuclear cells with Epstein-Barr virus, 
and somatic cell hybrid lines containing various por- 
tions of chromosome 17 were maintained in culture as 
described by O’Connell et al. (1990). Skin fibroblasts 
were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, and pas- 
saged every 5-7 days with a trypsin/EDTA solution. 
Mononuclear cells were prepared from whole periph- 
eral blood by the LeucoPREP procedure according to 
the manufacturer’s instructions (Becton Dickinson 
and Company, Lincoln Park, NJ). Bone marrow aspi- 
rates (performed at, University Hospital, University 
of Utah Medical Center, with informed consent of the 
patients and Institutional Review Board approval) 
drawn into tubes with heparin were spun at 2000 rpm 
for 10 min in a tabletop centrifuge; the pellets were 
then used for preparation of total RNA (see below). 
Other tissues removed from patients for therapeutic 
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reasons or at autopsy were immediately placed in liq- 
uid nitrogen and stored at -135°C until used for RNA 
preparation. Some tissue specimens were obtained 
from the National Neurological Research Bank, 
VAMC Wadsworth (Los Angeles, CA) which is spon- 
sored by NINCDS/NIMH, NMSS, HD Foundation, 
TS Association, and the Veterans Administration. 
RNA Preparation and Analysis 
Total RNA from peripheral blood mononuclear 
cells, bone marrow aspirates, and cultured cells was 
prepared either by the guanidinium-acid-phenol 
method as described by Chomczynski and Sacchi 
(1987) or by the vanadyl ribonucleoside complex 
(VRC) method described by Berger and Birkenmeier 
(1979). RNA from tissues that had been frozen in liq- 
uid nitrogen was prepared either by the guanidinium- 
acid-phenol method or by a procedure involving cen- 
trifugation in cesium chloride (Sambrook et al., 1989). 
Total RNA was electrophoresed through l-1.2% 
agarose gels containing formaldehyde and blotted 
overnight onto Duralon uncharged nylon membranes 
(Stratagene) or unto Hybond N nylon membranes 
(Amersham) essentially as described by Maniatis et 
al. (1982), except that 0.37 M formaldehyde was used 
in some of the gels as described by Selden (1989) and 
in the electrophoresis buffer as well instead of 2.2 M 
formaldehyde. Filters were crosslinked with uv irra- 
diation in a Stratalinker (Stratagene). Radiolabeling 
of probes for RNA analysis, hybridization, washing, 
and X-ray film exposures of RNA blots were per- 
formed as per the methods described above for 
screening cDNA libraries, except that preannealing of 
the probes was not performed in all cases. 
Sequencing 
All DNA sequencing was based on the dideoxy-ter- 
mination method of Sanger (Sanger et al., 1977). The 
insert from EVI2B cDNA clone D (EVI2BD) (XgtlO) 
was released by digestion with EcoRI, digested with 
Sau3AI and AluI, and subcloned into M13mp18; sin- 
gle-strand preparations were sequenced with fluores- 
cently tagged Ml3 primers on an Applied Biosystems 
Inc. Model 370A DNA sequencer (ABI, Foster City, 
CA), using T7 DNA polymerase or 7’aqI DNA poly- 
merase. To obtain sequence from the ends of clones 
EVI2BC and EVISBF, the inserts were released with 
EcoRI and subcloned into pUC19; double-stranded 
plasmid preparations were made by the cesium chlo- 
ride/ethidium bromide centrifugation method (Man- 
iatis et al., 1982), denatured by treatment with 0.2 N 
NaOH, neutralized, and sequenced from Ml3 primers 
on the ABI machine. To confirm sequences obtained 
by the above methods and to bridge gaps remaining in 
the cDNA sequences, oligonucleotide primers were 
synthesized on the basis of sequences obtained above 
and used in combination with primers based on 
pUCl9 or XgtlO vector sequences to make single- 
stranded DNA preparations from each of the above 
cDNA clones and EVIBBE by the asymmetric poly- 
merase chain reaction (Gyllensten, 1989). These sin- 
gle-st,rand preps were then sequenced on the ABI ma- 
chine. 
The inserts from EVIBB cDNA clones A and B in 
Xgtll were released by digestion with EcoRI and sub- 
cloned into the EcoRI site of Bluescript. Small-scale 
plasmid preparations (Holmes and Quigley, 1981) 
were subsequently used as template for dideoxy man- 
ual sequencing with Sequenase Version 2.0 (United 
States Biochemical Corp., Cleveland, OH). Essen- 
tially the same strategy as that described above was 
employed to sequence fully both strands of each clone. 
DNA sequence from cosmid clone cEVI20 was ob- 
t,ained by multiplexed dideoxy sequencing of random 
shotgun clones as described previously (Cawthon et 
al., 1990b). 
DNA and Peptide Sequence Analysis 
DNA sequences were aligned, examined for open 
reading frames, and compared to DNA sequences in 
the EMBL and GenBank databases using the Intelli- 
Genetics Suite of programs (IntelliGenetics Inc., 
Mountain View, CA) and the Wisconsin GCG Analy- 
sis Package (Devereux et al., 1984). The predicted 
EVI2B peptide was analyzed for hydropathy by the 
method of Kyte and Doolittle (1982) and compared to 
peptide sequences in the Swiss-Prot and PIR protein 
databases, again using the IntelliGenetics Suite. The 
most likely site for cleavage of the putative signal 
peptide was determined using the SIGSEQl and SIG- 
SEQ2 programs of Folz and Gordon (1987), based on a 
weight-matrix method developed by von Heijne 
(1986). 
Mapping EVIZB cDNAs onto Human and Mouse 
Genomic DNA 
Human genomic cosmid clones of cEVI20 and 
cEVI36 were digested with EcoRI or BglII, and mouse 
genomic X phage clones spanning the Eui-2 region 
were digested with EcoRI or XbaI. The digested 
clones were then electrophoresed through Tris-ace- 
tate-agarose gels and Southern-blotted onto nylon 
filters. To map the 3’ exon of EVI2B, a PCR product 
containing the entire open reading frame of E VIZB 
was radiolabeled (Feinberg and Vogelstein, 1984) and 
hybridized to and washed from these filters essen- 
tially as described in the next section. To map the 5’ 
exon of EVI2B, the exon was synthesized as a 60-bp 
oligonucleotide, 5’end-labeled with polynucleotide ki- 
nase and [Y~~P]ATP, and hybridized overnight to the 
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filters in 6X SSCP, 1% SDS, 5X Denhardt’s and 0.5 
mg/ml denatured salmon sperm DNA. The filters 
were washed in 2X SSCP, 1% SDS and visualized by 
autoradiography with X-Omat film and two intensi- 
fying screens at --70°C. 
Screening for NFl Mutations 
Human DNA samples (5-10 pg) were restriction 
enzyme-digested essentially according to instructions 
supplied by the manufacturer (Molecular Biology Re- 
sources, Bethesda Research Laboratories, and 
Boehringer-Mannheim). Restriction enzyme-di- 
gested samples were fractionated on 0.81% agarose 
gels in TEAC or TBE buffer and transferred either to 
Gelman Biotrace RP filters in 0.4 M NaOH (Reed and 
Mann, 1985) or to Hybond N in 10X SSC essentially 
as described by Southern (1975). Radiolabeling of 
DNA probes was done according to Feinberg and Vo- 
gelstein (1984). DNA plugs for PFGE were prepared 
in low-melt.ing-point agarose (Schwartz and Cantor, 
1984) and run on a variety of boxes including FIGE 
(Carle and Olsen, 1984), TAFE (Gardiner et al., 1986), 
and CHEF (Chu et al., 1986). Electrophoresis took 
place in 1.0-1.5s agarose gels in 0.5~ TBE buffer; 
DNA gels were depurinated by two 5-min washes in 
0.25 M HCl, immediately before transfer. 
Hybridizations took place in 50% formamide, 5X 
SSC, 50 mM NaPO, (pH 6.5), 2~ Denhardt’s solu- 
tion, and 200 pg/ml sheared, denatured human DNA 
at 42°C or in 1 MNaCl, 10% dextran sulfate, 1X Den- 
hardt’s solution, 1% SDS, and 100 pg/ml sheared, de- 
natured salmon sperm DNA at 65°C. Washes were in 
0.1X SSC, 0.1% SDS at 55-65°C. 
PCR-SSCP (polymerase chain reaction-single- 
strand conformation polymorphism) screening was 
performed as described by Orita et al. (1989). Radiola- 
beling of the PCR products was accomplished by in- 
corporation of [3”P]dCTP during the PCR reaction as 
described. 
RESULTS 
Isolation of EVI2B cDNA Clones 
The inserts of two cosmid clones, cEVI20 and 
cEVI36, are overlapping genomic DNA segments that 
span the 60-kb interval between the two NFl translo- 
cation breakpoints (O’Connell et al., 1990). The insert 
from cEV136 was used to screen an oligo(dT)-primed 
cDNA library from normal human bone marrow in 
XgtlO. Thirteen positive clones (from 1 X lo6 plated 
plaques) were picked and plaque-purified (Cawthon et 
al., 1990b); rescreening these 13 with the murine Eui- 
2A cDNA BK3 as probe identified 4 as being related 
to Eui-2A. Subsequently, cDNA clones representing 
sequences further 5’ in the human EVI2A mRNA 
were synthesized using the anchored PCR technique 
(Loh et al., 1989); these new EVIZA cDNAs were then 
shown to hybridize t,o an additional fifth clone from 
the original 13 bone marrow cDNA clones (Cawthon 
et al., 1990b). Therefore, 8 bone marrow cDNA clones 
appeared to be unrelated to EVI2A. The 3.7-kb insert 
from the largest of these 8 hybridized to all 8 clones 
and to none of the 5 EVI2A-related clones. These re- 
sults indicate that all 8 cDNA clones belong to a class 
independent from E VI2A cDNAs. 
Cosmid cEVI20 served as the starting point for an 
approach that resulted in the subsequent cloning of 
two additional independent cDNA clones related to 
the eight described above. A jump clone, pEH1 (Wal- 
lace et al., 1990b), was obtained by screening a jump- 
ing library with a 1..2-kb fragment of a 4.4-kb EcoRI 
subclone from the cosmid cEVI20 (O’Connell et al., 
1990). The insert of pEH1, consisting of 4.6 kb par- 
tially overlapping with cEV120 (beginning of jump, 
BOJ) (Fig. 5) as well as 5.7 kb derived from the end of 
jump approximately 50-60 kb further telomeric along 
the chromosome, was used as a probe against an RNA 
panel. A transcript was detected in B Iymphoblasts, 
and EHl was subsequently used as a probe to screen 
the human B-lymphoblast cDNA library in hgtll. Of 
5 X 10” pfu screened, five positive clones were picked, 
plaque-purified, and subcloned. Mapping experi- 
ments showed that these cDNA clones were identified 
by the portion of pEH1 that is the beginning of jump. 
The insert size of four of these clones was 0.9 kb and 
the size of the fifth clone was 1.2 kb. Sequencing of the 
clones showed the four 0.9-kb clones to be identical 
(EVI2BA), whereas the 1.2-kb clone (EVIBBB) and 
the 0.9-kb clones showed an overlap of 378 bp. 
Mapping the EVI2B cDNAs between the NFI 
Translocation Breakpoints 
Somatic cell hybrid lines containing NFl translo- 
cation chromosomes provide a means of precisely 
mapping genes relative to the translocation break- 
points. The cell line NF13 contains the derivative 
chromosome 22 [der(22)] from an NFl patient with a 
balanced translocation, t(17;22)(qll.2;qll.2) (Led- 
better et al., 1989). Cell line DCRl contains the 
derivative chromosome 1 [der(l)] from an NFl pa- 
tient wit.h a different balanced translocation, t(1;17) 
(p34.3;q11.2) (Menon et al., 1989). In both NF13 and 
DCRl cell lines, the only chromosome 17 content is 
the portion of the long arm of 17 from the breakpoint 
to the telomere. Therefore, a gene mapping between 
the breakpoints would be expected to hybridize to 
DNA from the hybrid cell containing the proximal 
translocation breakpoint, but would show no hybrid- 
ization to DNA from the hybrid containing the distal 
translocation breakpoint. Figure 1 shows the hybrid- 
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FIG. 1. (a) Chromosome 17 content of somatic cell hybrid cell lines constituting the mapping panel for the NFZ region. The name ofeach 
cell line is listed on the right; the portion of chromosome 17 present in each cell line is indicated by a line segment overlying the diagram of 
the chromosome; the NFI region between the translocation breakpoints is shaded (not shown to scale). (b) Hybridization of radiolabeled 
EVI2B cDNA D to Southern blots of EcoRI-digested total genomic DNAs from human and mouse and somatic cell hybrid DNA from the 
mapping panel. The 9.5- and 7.3.kh hands are indicated. Cell line L(17n)D contains an entire human non-NFI chromosome 17; cell line NF9 
includes the translocated chromosome 17 proximal to the t(17:22) break and contains the (noniranslocated) chromosome 17 homolog as 
well. 
ization results for cDNA EVI2BU. EVIBBD detects a 
single-copy locus. There is an EcoRI restriction frag- 
ment length polymorphism with two common alleles 
in the population (Andersen et al., 1990), identical to 
that detected by the genomic fragment clone pHU39 
(O’Connell et al., 1990). Both alleles, 9.5 and 7.3 kb, 
are represented in Fig. 1. The absence of the human 
band in the NF13 lane shows that EVI2B sequences 
are missing from the portion of the long arm of chro- 
mosome 17 that is distal to the t(17;22) breakpoint. 
The presence of the human band in t,he DCRl lane 
indicates that EVI2B sequences are present in the 
segment of chromosome 17 distal to the t(1;17) break- 
point. The NF9 hybrid cell line is also derived from 
the patient with the t(l7;22) balanced translocation. 
Its karyotype includes the portion of the translocat,ed 
chromosome 17 that is proximal to the break, and the 
homologous chromosome 17 as well (D. Ledbetter, 
personal communication). Since both the 9.5- and 
7.3-kb alleles are seen in the NF9 cell line, we can 
conclude that the t(17;22) translocation does not in- 
volve a deletion that removes the EVI2B locus. 
EVI2B, therefore, maps to a region between the NFl 
translocation breakpoints. 
Analysis of EVI2B mRNA Expression 
EVI2B cDNAs identify a 2.1-kb transcript on RNA 
blots of bone marrow and other tissues (Fig. 2). With 
autoradiographic exposures of l-3 days the EVI2B 
transcript was most abundant in 5-pg samples of total 
RNA from peripheral blood mononuclear cells, bone 
marrow, Epstein-Barr virus (EBV)-transformed lym- 
phoblastoid cell lines, and T cells and detectable in 
fibroblasts. No significant difference in the level of 
expression of EVI2B between T cells and EBV-trans- 
formed lymphoblasts (of B-cell origin) was detected. 
With prolonged autoradiographic exposures (10 days) 
E VI2B transcripts were detected in peripheral nerve, 
neurofibroma, malignant schwannoma, adrenal 
gland, brain frontal cortex, and liver (data not 
shown); however, the low abundance of EVI2B tran- 
scripts in these pathologic specimens and autopsied 
tissues could be due to the presence of peripheral 
blood cells in the vasculature of these tissues. E VI2B 




FIG. 2. RNA blots of human tissues, probed with EL’128 
cDNAs. Approximately 5 rg of total RNA was loaded in each lane. 
The mohilities of RNA standards of known size are shown to the 
right. of the blots. EBV-transformed B cells grown in tissue culture 
are labeled “lymphohlast.” In the fourth lane, “p.b.” indicates “pe- 
ripheral blood.” T cells were fractionated from whole blood. Fihro- 
blasts were grown in tissue culture. Lanes 1 and 2 contain lympho- 
blast RNA from the NFl patients with the t(17;22) and t(7;17) 
halanced translocations; all other samples are from non-NF1 sub- 
jects. Lanes l-5 were exposed to film for 2 days: lanes 6 and 7 for :3 
days; and lane 8 for 5 days. 
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FIG. 3. Human EVI2B cDNA clones. The scale is in nucleotide 
base pairs. A and B are B-lymphoblast cDNAs. C’. 1). E, and F are 
hone marrow cDNAs. The stippled segments contain the EVI2R 
open reading frame. The solid white segments are 5’and 3’ noncod- 
ing EL’IZ? sequences. The cross-hatched segment in clone n. rep- 
resenting EVI2B intron sequences, is approximately 1.6 kb long 
and is not shown in its entirety. A,,, designates the presence of a 
poly(A) tail. Clones E and Fare independent full-length cDNAs, 
differing at the 3’end but ending at the same base at the 5’ end. In 
the genome an intron. approximately 8 kb in length, interrupts the 
sequence of clones E and Fat the position indicated by the arrow. 
A second transcript, approximately 1.9 kb, was de- 
tected in fibroblasts (Fig. 2) and, after longer (5-day) 
autoradiographic exposures, also detected in EBV- 
t,ransformed lymphoblasts (data not shown). Appar- 
ently, the relative proportion of the 2.1- and 1.9-kb 
transcripts varies in different tissues. Characteriza- 
tion of cDNA clones from the bone marrow and B- 
lymphoblast cDNA libraries (see next section) sug- 
gests that the 1.9-kb transcript probably is identical 
to the 5’ 1.9 kb of the 2.1-kb transcript. 
The blot shown in Fig. 2 includes RNA samples 
from the two NFl lymphoblastoid cell lines contain- 
ing, respectively, the t(17;22) and t( 1;17) balanced 
translocations. E VIZB transcripts of abnormal mobil- 
ity were not detected in these samples. Furthermore, 
EBV-transformed lymphoblast RNAs from 20 unre- 
lated NFl patient,s and 7 non-NFl controls were 
screened with cDNA clone EVl2BD or a mixture of 
EVIBBA and B. No EVIZB transcripts of aberrant 
mobility were found, and no significant difference in 
the levels of expression of EVIZB between NFl sam- 
ples and controls was detected. 
cDNA and Genomic Nucleotide Sequences and 
Predicted Amino Acid Sequence of EVIZB 
Figure 3 is a schematic representation of several of 
the EV12B cDNA clones that we have isolated. 
EVI2BE and EVIBBF appear to be independent, full- 
length EVI2B cDNA clones. The EVIBBE and 
EVI2BF sequences are identical for 1915 bp, begin- 
ning with the first base pair at their 5’ ends. EVI2BE 
terminates 3’ of bp 1915 in a poly( A) tract containing 
23 A’s, but EVIBBF continues without a poly(A) tract 
through bp 2135, then ends with a tract of 12 A’s. The 
size of EVIBBF fits well with the size of the major 
transcript seen on RNA blots; EVIBBE may represent 
the smaller size transcript. Clone EVI2BB also ap- 
pears to be derived from the smaller transcript. Its 
sequence is identical to the sequence of a segment of 
the EVIBBF cDNA, but like cIone EVIZBE, its 3’ end 
terminates approximately 220 bp 5’of the 3’end of the 
EVI2BF sequence; however, the poly(A) tract for 
EVIBBB begins one base further 3’ than does the 
poly(A) tract of EVIBBE. Clones EVIBBC and 
EVIBBD terminate at their 3’ends at the same base as 
clone EVIZBF. The sequences of clones EV12BB and 
EVI2BC do not continue as far 5’as those for EVIBBE 
or EV12BF, presumably due to incomplete first- 
strand cDNA synthesis during t,he construction of the 
cDNA libraries. EVIBBA is identical in sequence to a 
segment of EVIBBF, it lacks a poly(A) tract, and it 
overlaps EV12BB for 378 bp. EVIBBD is 3.7 kb long 
and appears to be derived from an unprocessed 
EVIZB RNA (see below). 
Comparing the cDNA sequences to genomic se- 
quences obtained from a cloned cosmid, cEVI20 
(Weiss, in preparation), we were able to determine 
that in the genome an intron interrupts the sequence 
of cDNA clones EVIBBE and EVIBBF at the point 
indicated in Fig. 3. The first 57 bp at the 5’ end of the 
EVIBBE and EVIBBF cDNA clones are identical to a 
57.bp genomic sequence that is contained within one 
cosmid subclone; further 3’ the genomic sequence di- 
verges from the cDNA sequence. The sequence 
around the divergence point (with capital letters for 
sequence shared by cDNAs and genome, small letters 
for sequences present, only in the genome, and a slash 
to mark the divergence point) is GAG/gtaaga, which 
approximates the primate 5’ splice site consensus se- 
quence NAG/gtragt (Shapiro and Senapathy, 1987). 
The next 94 bp of EVISBE and EVIBBF cDNA se- 
quence are identical to the last 94 bp of a sequenced 
portion of another cEVI20 cosmid subclone; however, 
the genomic sequence 5’ of these 94 bp diverges from 
the cDNA sequence. The sequence around this diver- 
gence is cccgctatag/ATAACG, consistent with a 3’ 
splice junction. Mapping studies (presented below) in- 
dicate that this intron is approximately 8 kb long and 
that there are no additional introns. cDNA EVIBBD 
apparently is derived from an unprocessed EVI2B 
transcript; it is 3.7 kb long, lacks the 57-bp 5’ exon 
found in clones EVI2BE and EVIBBF, and matches 
cDNA EVIBBF starting just 3’ of the 3’ splice junc- 
tion described above and continuing up to the begin- 
ning of the poly(A) tails (2078 bp). In addition, 5’ of 
the sequence shared with EVI2BF, the sequence of 
clone EVIBBD matches the genomic sequence lying 
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immediately 5’ of this 3’ splice junction in a cEVI20 
subclone. 
Although we have not yet sequenced all of the geno- 
mic DNA that gives rise to the full-length EVI2B 
cDNAs, experiments indicate that the cDNA se- 
quences 3’ of the 57 bp exon described above are not 
interrupted in the genome. First, a PCR experiment 
was performed using as primers an oligonucleotide lo- 
cated in the already identified intron, within the 40 bp 
adjacent to the 3’ splice junction, in combination with 
a primer located in the EVISBF cDNA sequence 
within the 25 bp adjacent to the poly(A) tail. Single 
amplified products, indistinguishable in size by aga- 
rose gel electrophoresis and ethidium bromide stain- 
ing, were obtained from genomic DNA, from cosmid 
cEVI36, and from cDNA clone EVI2BD (data not 
shown). Furthermore, six pairs of oligonucleotide 
primers based on sequences located within cDNA 
clone EVIBBD have been used to PCR-amplify a con- 
tiguous set of overlapping segments (approximate 
length 400 bp per segment) that includes all of the 
EVIBBF cDNA sequence between the known 3’ splice 
junction and the poly(A) tail. For each of the primer 
pairs, the amplified products from genomic DNA, 
cEVI36, and cDNA EVISBD were indistinguishable 
in size by gel electrophoresis in 4% agarose gels and 
ethidium bromide staining. These results indicate 
that the terminal 2078 bp of cDNA EVIXBF are most 
likely uninterrupted in the genome, and therefore 
constitute a single exon. 
The cDNA sequence, genomic splice-junction se- 
quences, predicted amino acid sequence, and a hydrop- 
athy plot of human E VI2B are shown in Figs. 4a and 
4b. The intervening sequence lies between nucleotide 
positions -21 and -22 of the cDNA sequence. A sin- 
gle, large open reading frame (ORF) extends from the 
A at the fl position to the T at +1344. The ATG 
starting at position +l is the first ATG in this reading 
frame, and it matches the Kozak consensus initiation 
sequence 5’-RNNATGG-3’ for eukaryotic mRNAs 
(Kozak, 1984). There are frequent stop codons in both 
of the remaining two reading frames. 
The EVI2B ORF predicts a 448-amino-acid pro- 
tein. The N-terminal segment has features suggesting 
a signal peptide (von Heijne, 1985; Gierasch, 1989), 
with cleavage most likely occurring after the serine 
residue at position 21 (von Heijne, 1986; Folz and 
Gordon, 1987). Next is a 181-residue hydrophilic, pre- 
sumably extracellular domain, with four potential N- 
glycosylation sites (nx(s/t)). Then follows a segment 
of 24 hydrophobic amino acids with an average hy- 
dropathy score of 2.6 by a Kyte and Doolittle (1982) 
analysis that indicates it is a transmembrane domain. 
The remaining hydrophilic domain of 222 amino acid 
residues is presumably cytoplasmic. Like the hydro- 
philic domain amino-terminal to the transmembrane 
domain, this hydrophilic domain carboxy-terminal of 
the transmembrane domain also has four potential 
N-glycosylation sites. EVI2B is proline-rich; 47 of the 
448 amino acids are proline (10.5%), and there are 
five proline doublets, one stretch of four consecutive 
prolines, and one stretch of five consecutive prolines. 
There are six cysteine residues, one in the putative 
signal peptide and five carboxy-terminal to the trans- 
membrane domain. Structural motifs characteristic 
of known oncogenes have been sought, but not de- 
tected. Comparison of the cDNA sequence to se- 
quences in the EMBL and GenBank databases, com- 
parison of the predicted peptide sequence to peptides 
obtained by translating the DNA database sequences 
in all six reading frames, and comparison of the pre- 
dicted peptide to protein sequences in the PIR and 
Swiss-Prot databases have shown that EVI2B is a 
novel gene with no significant specific similarities to 
previously reported DNA or protein sequences. 
The 3’ untranslated sequence of the E VI2B mRNA 
contains four instances of the AUUUA pentamer. 
This motif is common to the 3’ untranslated regions 
of many oncogene and cytokine mRNAs, and it ap- 
pears to promote rapid cytoplasmic degradation of 
mRNAs (Shaw and Kamen, 1986; Greenberg et al., 
1986; Wilson and Treisman, 1988; Brawerman, 1989; 
Malter, 1989). 
Location of EVI2B with Respect to the NFl 
Translocation Breakpoints 
As shown in Fig. 5, the entire EVI2B full-length 
cDNA sequence (i.e., the entire sequence of the 
EVI2BF cDNA) lies within the interval between the 
translocation breakpoints and consists of two exons 
separated in genomic DNA by an 8-kb intron. Tran- 
scription is in the direction indicated by the arrow; 
i.e., the 5’ end of the sense strand is toward the telo- 
mere of 17q. This genomic organization was deduced 
from the following experiments. 
The BamHI and EcoRI restriction map of the 
breakpoint region and the BglII restriction map of 
cosmid cEVI36 (O’Connell et al., 1990) are shown in 
Fig. 5. To locate the E VI2B 3’ exon on this restriction 
map, cDNA EVI2BC, which consists of the terminal 2 
kb of the 3’ exon, was radiolabeled and hybridized to 
Southern blots of BamHI- and EcoRI-digested 
cEVI20 and cEVI36 cosmid clones. In BamHI/EcoRI 
doubly digested samples, only the 1.2-kb BamHI cen- 
tromeric end fragment of cosmid cEVI20 and the 6-kb 
EcoRI/BamHI fragment of cEVI36 that this cEVI20 
end fragment overlaps hybridized to the EVIBBC 
probe. The centromeric end of cEVI20 has been se- 
quenced for 267 bp; comparison to the sequence of the 
E VI2B cDNAs showed that these 267 bp are identical 
to bp 893-1159 of the EVI2BF sequence (Fig. 4a) and 
5' CAAAATGTCCAGTTAGAACAAGAATTTAGCATTCTGCAAAAGAA -215 
GTTMCAGCTCAGgtaegaaeattttcacacaatttggtttgatcttgctttatataaaatttattttaaaactgtcattagtgttttaaacttaaactctgatagt -108 
cte . ..eatataatgaaaagtcaaagttttaactagacaccaatgacgcctaactgtctttctctttcattataaacccgctata~TMCGAGG~TATTCTGM -1 




ACA GAG AAG CAG TCA CAG CCT ACC TTA TAC ACA TCA TCA ATG TCA CAG GTA TTG GCT MT TCT CM MC ACA ACA GGG MT 162 
TEKPSPPTLYTSSHSQVLANSQNTTGN 54 
CCT TTG GGT CM CCA ACA CM TTC AGC GAC ACT TTT TCT GGA CM TCA ATA TCA CCT CCC AAA GTC ACT GCT CGA CM CCA 243 
PLGPPTPFSDTFSGPSISPAKVTAGQP 81 
ACA CCA GCT GTC TAT ACC TCT TCT GAA AAA CCA GAA GCA CAT ACT TCT GCT CGA CM CCA CTT GCC TAC MC ACC AAA CM 324 
TPAVYTSSEKPEAHTSAGQPLAYNTKQ 108 
CCA ACA CCA ATA GCC MC ACC TCC TCC CAG CM GCC GTG TTC ACC TCT GCC AGA CM CTA CCA TCT GCC CGT ACT TCT ACC 405 
PTPIANTSSPQAVFTSARQLPSARTST 135 
ACA CM CCA CCA MG TCA TTT GTC TAT ACT TTT ACT CM CM TCA TCA TCT GTC CAG ATC CCT TCT AGA AAA CM ATA ACT 486 
TPPPKSFVYTFTQPSSSVQIPSRKQIT 162 
GTT CAT MT CCA TCC ACA CM CCA ACA TCA ACT GTC AAA MT TCA CCT AGG AGT ACA CCA GGA TTT ATC TTA CAT ACT ACC 567 
VHNPSTPPTSTVKNSPRSTPGFILDTT 189 
ACT MC AAA CM ACC CCA CM AAA MC MT TAT MT TCA ATA GCT GCC ATA CTA ATT GGT GTA CTT CTG ACT TCT ATG TTG 648 
SNKPTPPKNNYNSIAAILIGVLLTSML 216 
GTA GCT ATA ATC ATC ATT GTA CTT TGG AAA TGC TTA AGG AAA CCA GTT TTA MT GAT CM MT TGG GCA GGT AGA TCT CCA 729 
VAIIIIVLWKCLRKPVLNDPNUAGRSP 243 
TTT GCT GAT GGA GAA ACC CCT GAC ATT TGT ATG GAT MC ATC AGA GM MT GM ATA TCC ACA AAA CGT ACA TCA ATC ATT 810 
FADGETPDICMDNIRENEISTKRTSII 270 
TCA CTT ACA CCC TGG AAA CCA AGC AAA AGC ACA CTT TTA GCA GAT GAC TTA GM ATT MG TTG TTT GM TCA ACT GM MC 891 
SLTPUKPSKSTLLADDLEIKLFESSEN 297 
ATT GM GAC TCC MC MC CCC AAA ACA GAG AAA ATA AAA CAT CM GTA MT GGT ACA TCA GAA CAT AGT GCT GAT GGT TCA 972 
IEDSNNPKTEKIKDPVNGTSEDSADGS 324 
ACA GTT GGA ACT GCT GTT TCT TCT TCA GAT GAT GCA GAT CTG CCT CCA CCA CCT CCC CTT CTG GAT TTG GAA GGA CAG GM 1053 
T V G T A V S S S D DADLPPPPPLLDLEGPE 351 
AGT MC CM TCT GAC AAA CCC ACA ATG ACA ATT GTA TCT CCT CTT CCA MT GAT TCT ACT ACT CTC CCT CCA TCT CTG GAC 1134 
S N P SD K P T H'T I V S P L P ND S T S L P P S L D 378 
TGT CTC MT CM GAC TGT GGA GAT CAT AAA TCT GAG ATA ATA CM TCA TTT CCA CCC CTT GAC TCA CTT MC TTG CCC CTG 1215 
CLNPDCGDHKSEIIPSFPPLDSLNLPL 405 
CCA CCA GTA GAT TTT ATG AAA MC CM GAA GAT TCC MC CTT GAG ATC CAG TGT CAG GAG TTC TCT ATT CCT CCC MC TCT 1296 
PPVDFMKN4EDSNLEIQCQEFSIPPNS 432 
GAT CM GAT CTT MT GAA TCC CTG CCA CCT CCA CCT GCA GAA CTG TTA TM ATATTACMCTTGCTTTTTAGCTGATCTTCCATCCTCAA 1386 
DPDLNESLPPP PAELL. 448 
ATGACTCTTTTTTCTTTATATGTTMCATATATAAAATCGGCCTATGTGCATA 1493 





ACACCCAAACAAAATCMGTTTTATAAACAAAAAAAAAAAA 3' 2057 
FIG. 4a. cDNA and genomic nucleotide sequences and predicted amino acid sequence of EVIZB. The EVZ2B F cDNA nucleotide 
sequence is capitalized; genomic sequences from the intron are in lowercase. The cDNA sequence is numbered beginning with the put.ative 
initiating ATG codon and ending with the G nucleotide at position 2057; this G is followed by a series of 12 A’s that end at the EcoRI cloning 
site of the vector. Sequences in the intron are not numbered; ellipses represent the omitted portion of the 8-kb intron. In the open 
reading frame the one-letter amino acid translation is shown below each codon; the arrowhead between predicted amino acids 21 and 22 
indicates the most likely cleavage site for the putative signal peptide; single underlining denotes potential sites for N-linked glycosylation; 
and double underlining indicates the strongly hydrophobic, presumably transmembrane segment of the predicted protein. In the 3’ noncod- 
ing sequence single underlining identifies potential polyadenylation signals, and double underlining marks a reiterated pentamer shared by 
rapidly degraded mRNAs. 
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FIG. -ib. Hydropathy profile of predicted EVIZB protein. Deflections above zero indicate hydrophobic regions, 
that the cDNA sequence is oriented with its 3’ end to the directionality of jumping (Collins et al., 1987) 
toward the centromere. In line with this? 199 bp of the the orientation of this segment was known and thus 
beginning of the jumping clone EHl, from which the the 3’ end of the cDNA clones could be determined to 
cDNA clones EVI2BA and EVI2BR were derived, was be toward the centromere. 
sequenced. These base pairs are identical to bp 1138- To locate the 5’ exon of the EVIBBF cDNA clone on 
1336 of EV12BF, also contained within EVIZB8. Due the restriction map of the breakpoint interval, an oli- 
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FIG. 5. Location of transcripts in the translocation-breakpoint region. The long open bar is a HamHI (B) and EcoKI (E) restriction map 
of the region of chromosome 17q containing the two NFl translocation breakpoints. The centromere is toward the left, the telomere toward 
the right. The t(l;lT) and t(17;22) breakpoints lie somewhere within the respective stippled sections. Below the restriction map are shown 
two genomic cosmids that span the region and a 4.6-kh segment of a jump clone, pEH1. The &III (G) restriction map of cosmid cEVI36 is 
included. Above the EcoRI/BamHI restriction map cDNA clones are represented as heavy arrows overlying the restriction fragments to 
which they hybridize. The length of an arrow or heavy bar is scaled to the length of the isolated cDNA; the direction of the arrow indirates 
the direction of transcription. 
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gonucleotide containing it was synthesized, end-la- 
beled with “*P, and hybridized to a Southern blot of 
EcoRI-digested cosmids cEVI20 and cEVI36. The 
only EcoRI fragment hybridized by this oligonucleo- 
tide is approximately 8.5 kb long and shared by both 
cosmids; this result places the EVI2B 5’ exon some- 
where within this restriction fragment (data not 
shown); in Fig. 5 the exon is shown overlying this 
EcoRI fragment. To determine the orientation and 
approximate location of the exon within the EcoRI 
fragment, PCR was performed using primers based on 
the sequenced genomic segment containing the exon, 
in combination with primers whose location on the 
map was known; cosmids cEVI20 and cEVI36 were 
used as template DNA. Primers from the EVI2B 5’ 
exon in combination with primers from the 3’ end of 
the 3’ exon of the EVI2A gene yielded single DNA 
bands by agarose gel electrophoresis and ethidium 
bromide staining. The sizes of these bands and the 
known positions of the EVI2A primers relative to the 
t.elomeric end of the EcoRI fragment locate and orient 
the EVI2B 5’ exon within the EcoRI fragment as 
shown in Fig. 5. The EVI2B 5’ exon lies only 4 kb 
centromeric of the 3’ end of the EVI2A polyadenyla- 
tion site. 
Taken together, the placements of the 5’ and 3’ ex- 
ons on the restriction map of the breakpoint region 
indicate that the E VI2B intron is approximately 8 kb 
in size. 
As shown in Fig. 5, the polyadenylation site of 
EVI2B cDNA clone F lies approximately 5 kb up- 
stream from the 5’ most sequences known to be a part 
of the OMGP 5’exon (Viskochil et al., 1990). OMGP is 
the gene encoding the oligodendrocyte-myelin-glyco- 
protein (Mikol et al., 1990). 
Identification of the Murine Homolog of EVI2B: 
Genomic Organization and Proximity to Evi-2A 
Evi-2A (in previous publications designated Evi-2) 
was originally identified as a common site of viral in- 
tegration in virally induced myeloid tumors in BXH-2 
mice (Buchberg et al., 1988, 1989, 1990); this finding 
suggested that Evi-2A could be a proto-oncogene. 
Since the EVI2B locus in the human was found to be 
located quite near human E VI2A, the possibility was 
raised that the murine homolog of EVI2B is similarly 
located close to murine Evi-2A, is affected by the viral 
integrations, and contributes to tumor formation in- 
dependently or in conjunction with murine Evi-2A. 
Figure 6 is a map of murine genomic DNA from chro- 
mosome 11, showing the location and orientation of 
the integrated proviruses within the Evi-2A locus 
with respect to the exons of Evi-2A. In general, for 
any particular tumor only a single viral integration 
occurred in the vicinity of Evi-2A (exceptions are de- 
scribed below); the figure compiles the various sites 
found in surveying the DNA from several tumors. As 
can be seen, four viral integrations occur within the 
intron of Evi-2A, three occur within the 3’ exon, one 
occurs 5’ of the gene, while six occur 3’ of Evi-2A 
(Buchberg et al., 1990). To determine the location of 
the murine homolog of EVI2B, we first used a cDNA 
probe representing the 3’ exon of human EVI2B. In 
the mouse the genomic DNA segment identified by 
this probe lies 5.6 kb from the 3’ end of Evi-2A, a 
location homologous to that in the human. Moreover, 
using a 60-bp probe representing the 5’exon of human 
E VI2B, the corresponding murine genomic DNA seg- 
ment was localized to a 500-bp BamHI-EcoRI frag- 
ment located 2.8 kb from the 3’ end of Evi-2A. The 
location of this 5’ exon puts it in the midst of the viral 
integrations occurring 3’ of Evi-2A (Fig. 6). 
Search for EVI2B Mutations Specific to NFl Patients 
As yet, no mutations in EVI2B specific to NFl pa- 
tients have been found, although several techniques 
capable of detecting different types of mutation have 
been applied in the course of this search. All NFl 
patients were diagnosed by the criteria of Stumpf et 
al. (1987). To screen for large-scale deletions or inser- 
tions in the region of EVI2B, EVI2B cDNA clones 
were used to probe Southern transfers of genomic 
DNA from 38 independent NFl lymphoblastoid cell 
lines and several non-NFl controls, after digestion of 
the DNA with rarely cutting restriction endonucle- 
ases (NruI, SacII, and NotI) followed by pulsed-field 
gel electrophoresis. To screen for medium-scale dele- 
tions or insertions, these same probes were used to 
screen Southern transfers of genomic DNA from 126 
unrelated NFl patients after digestion with restric- 
tion enzymes with six-base recognition sites (EcoRI 
and BamHI) and standard agarose gel electrophore- 
sis. To screen for small deletions, small insertions, 
and point mutations in the ORF of EVI2B, we ana- 
lyzed genomic DNA from four sporadic NFl patients 
and their eight (unaffected) parents, by the PCR- 
SSCP method of Orita et al. (1989); for each individ- 
ual, four pairs of oligonucleotide primers were used to 
amplify four overlapping segments (approximately 
380 bp each) encompassing the entire EVI2B ORF, 
and the amplified products were heat-denatured and 
subjected to electrophoresis through 4-5% nondena- 
turing polyacrylamide gels. The EVI2B ORFs from 
an additional 40 unrelated NFl patients were also ex- 
amined by PCR-SSCP; however, for these samples 
the entire ORF was amplified as part of a single 1.5-kb 
PCR product, then digested with either Alu I or Sau 
3A I prior to heat denaturation and gel electrophore- 
sis. None of the above procedures identified a restric- 
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FIG. 6. Restriction map of the murine Eoi-ZA-Eui-2B region. The restriction map of the region, represent,ed by the solid line, was 
generated using EcoRI (R), KpnI (Ii), SstI (S), and XbaI (X). The KpnI site at the right end of the map was determined by Southern blot 
analysis of genomic DNA. The cross-hatched boxes (A-E) ahove the restriction map represent the location of five unique sequence probes 
from the region (12). The checkered hoxes represent the two exons of 1Sui-PR. The solid box represents the transcribed region that is shared 
in common by the two Eui-2A transcripts found in mouse tissues; the two hatched boxes represent the regions unique t,o each of two ELC2A 
cDNA clones. The location and orientation of proviral integrations in each tumor are shown beneath the rrstrict,ion map. The pairs of 
proviral integrations in tumors 82-10. 82-97, and RB30 are arbitrarily labeled a and b. 
tion fragment of PCR product specific to NFl pa- 
tients. 
DISCUSSION 
The proximity of murine EVZ2B to a common site 
of viral integration in virally induced myeloid tumors 
suggests that this locus may encode a proto-oncogene. 
BXH-2 mice express chronic leukemia viruses begin- 
ning at Days 14-16 of gestation (Bedigian et al., 1981). 
These viruses induce disease in susceptible hosts via 
the insertional activation or mutation of cellular 
proto-oncogenes (reviewed by Copeland et al., 1989). 
Since retroviruses integrate into many distinct sites 
in the host genome, the detection of a common viral 
integration site in tumors suggests that the locus en- 
codes a gene whose activation or mutation by viral 
integration predisposes the target cell to neoplastic 
disease. Evi-2A was found to be a site of viral integra- 
tion in 11 of 69 BXH-2 tumors analyzed, interest- 
ingly, three of these tumors had two independent in- 
tegrations within the Eui-2A locus (Buchberg et al., 
1990). A transcription unit was identified, within the 
region defined by the viral integration sites, that is 
capable of encoding a 223-amino-acid protein that 
has all the structural hallmarks of a transmembrane 
protein containing a leucine zipper within the trans- 
membrane domain (Buchberg et al., 1990). However, 
since we did not have a source of RNA from the tu- 
mors containing viral integrations within the Eui-2A 
locus, we were unable to determine whether viral in- 
tegrations altered Eui-2A expression. 
The location and orientation of the eight integrated 
proviruses located 5’ or wit,hin Evi-2A gene (see Fig. 6) 
are consistent with their being involved in the alter- 
ation of transcription of the Eui-2A locus. However, 
viral integrations that occur at the 3’ end of genes 
usually are oriented in the same transcriptional orien- 
tation as the gene they affect (Copeland et al., 1989), 
though there have been reports of viral integrations in 
the opposite transcriptional orientation (Morris et al., 
1990). Of the six proviral integrations 3’ of Eui-2A, 
one is in the same orientation, four are in the opposite 
orientation, and one has an unknown orientation. 
The large number of integrations in the 3’ end of Eui- 
2A in the orientation opposite from that of Eui-2A 
locus suggests either a novel mechanism of gene acti- 
vation or the presence of another transcript in the 
vicinity (e.g., Eui-2B) t,hat the viruses are affecting. 
Additionally, of t,he three tumors that had two inde- 
pendent integrations, one integration occurred within 
the Evi-2A coding region while the second integration 
occurred in the 3’ end of Evi-BA, suggesting that ei- 
ther two hits are better than one or, alternatively, two 
genes are being affected. 
Thus it, is possible that these viral integrations are 
aEecting the expression of Eui-2B, as well as or in- 
stead of Eui-2A. It, has been previously observed that 
viral integrations can affect the expression of several 
closely linked genes (Peters et al., 1989). For example, 
integration of mouse mammary tumor virus (MMTV) 
between two fibroblast growth factor-related pro- 
tooncogenes, Znt-1 and Hst, which are located within 
17 kb of one another on mouse chromosome 7, can 
activate the expression of both genes (Peters et al., 
1989). The activation of Znt-1 and Hst expression by 
MMTV is thought to be important in the induction of 
mammary tumors by MMTV. Integration of Mo- 
loney-MuLV int,o the Put-l locus has been shown to 
activate the expression of c-myc (Tsichlis et al., 1989), 
which is located 260 kb proximal of Put-l (Henglein et 
nl., 1989), leading to the development of T-cell lym- 
phomas in rat.s. The Put- 1 locus is part of a large gene 
that occupies a minimum of 200 kb of DNA and be- 
gins 57 kb distal of c-myc (Shtivelman et al.. 1989). 
Viral int,egrations in Put-l not only activate the ex- 
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pression of c-myc but also affect the expression of 
Put-l (Tsichlis et al., 1989). While the role of the Pvt- 
1 gene in tumor formation is unknown, it is clear that 
activation of c-myc is an important event in the in- 
duction of T-cell lymphomas in mouse and rat (Cor- 
coran et al., 1984; Selten et al., 1984; Steffen, 1984; 
Steffen and Nacar, 1988). Thus, the viral integrations 
found in the vicinity of the two Evi-2 loci in murine 
myeloid tumors may contribute to tumorigenesis by 
affecting the expression of the Evi-2B locus, in addi- 
tion to or instead of affecting the expression of Evi- 
2A. It is also possible that the viral integrations are 
affecting the expression of the murine homolog of the 
NFl gene and that murine NFl contributes to the 
production of the myeloid tumors. 
Although the predicted protein product of EVI2B 
has no significant sequence homology to the products 
of known oncogenes, it appears t.o be a glycosylated 
protein with a single membrane-spanning domain. 
Examples of transmembrane proteins that when mu- 
tated contribute to carcinogenesis include certain 
growth factor receptors (Ullrich et al., 1984; Barg- 
mann et al., 1986) and cell adhesion molecules 
(Fearon et al., 1990). Also, overexpression of growth 
factor receptors of normal structure can contribute to 
transformation in cell culture (Di Fiore et al., 1987). 
Studies of the relative abundance of Evi-2A, Evi-2B, 
and NFl transcripts in murine myeloid tumors con- 
taining viral integrations in the Evi-2 region may 
show specific activation of just one locus, supporting 
the designation of that locus as a proto-oncogene. Rig- 
orous tests of whether E VI2B has oncogenic potential 
may be possible by using expression vectors to deliver 
a normal or mutated EV12B gene product to normal 
or transformed cells in culture, then looking for any 
effect on t,he growth properties of the cells. EVI2B 
endogenous to a cultured cell line could be knocked 
out using an expression vector that produces RNA 
t,hat is anti-sense to the EVI2B mRNA; the conse- 
quences to cell growth could then be measured. Analo- 
gous studies could be performed in the intact mouse 
using transgene or homologous recombination t,ech- 
nology. 
In light of the possible roles of EVI2A and EVI2B 
in murine leukemogenesis and the abundance of 
EVI2A (Cawthon et al., 1990b) and EVI2B tran- 
scripts in peripheral white blood cells, it is worth not- 
ing that juvenile chronic myelogenous leukemias 
(JCMLs) have been reported to occur more often in 
NFl patient.s than in the general population (Bader 
and Miller, 1978; Mays et al., 1980; Clark and Hutter, 
1982). Perhaps certain mutations affect NFZ and 
EVI2A or NFl and EVI2B genes to produce the NFl/ 
JCML phenotype; mutat3ons affecting EVI2A and/or 
EVI2B without affecting NFl may predispose the in- 
dividual to acquiring particular leukemias. Our 
screens for mutations in the EVI2A (Cawthon et al., 
1990b) and EVI2B loci in NFl patients were com- 
pletely negative. Furt.hermore, examination of lym- 
phoblast RNA showed no significant differences in 
the abundance of EVI2A or EVI2B transcripts be- 
tween several unrelated NFl individuals and non- 
NFl controls. However, we have not yet thoroughly 
examined the sequence and expression of the EVI2 
region in NFl/JCML patients or in leukemia pa- 
tients. 
We are not aware of another example of three ac- 
tive genes (EVI2A, EVI2B, and OMGP; Viskochil et 
al., 1990b) located on the anti-sense strand of an in- 
tron of another gene (NFl). Some of the possible con- 
sequences of this arrangement have been discussed 
(Cawthon et al., 1990a; Wallace et al., 1990a). One 
interesting situation that may produce NFl in a small 
fract,ion of patients could involve a mutation that 
alters the splicing and transport to the cytoplasm of 
the EVI2B transcript. If the levels of this transcript 
in the nucleus become elevated, it might hybridize to 
the complementary segment of the NFl transcript, 
thereby promoting rapid degradation or interfering 
with the splicing of that intron. Such a mutation 
could be dominant with respect to NFI, yet recessive 
with respect to the normal function of E VI2B, since 
one copy of the normal E VI2B allele (provided by the 
chromosome 17 homolog) may be adequate to provide 
that function. Thus, in addition to yielding a wealth 
of information about the regulation of the NFl locus 
and mechanisms of mutation in NFl, the study of 
these four genes may generate principles of gene orga- 
nization, regulation, and interaction that can be ap- 
plied to other yet to be discovered systems of genes 
embedded within other genes. 
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